Olfr834, a member of the olfactory receptor family, plays a fundamental role in the intricate process of olfaction. Positioned on the surface of olfactory sensory neurons within the nasal epithelium, Olfr834 serves as a G protein-coupled receptor (GPCR) specialized in detecting and transducing signals from odorant molecules. Its primary mission is to act as a molecular sensor, capturing the presence of specific odorants in the environment. The functional significance of Olfr834 is deeply intertwined with its ability to recognize and interact with diverse odorant molecules, each possessing a unique chemical structure. When an odorant molecule binds to Olfr834, a series of conformational changes occur, initiating a cascade of intracellular events. Olfr834's activation leads to the generation of electrical signals, which are essential for the perception of odor. This process begins with the activation of adenylate cyclase, resulting in the production of cyclic AMP (cAMP). Elevated cAMP levels trigger downstream signaling components, including protein kinase A (PKA), which ultimately leads to the opening of ion channels. These ion channels allow for the influx of ions and the generation of action potentials, which are transmitted to the brain, where they are processed into the perception of odor. Olfr834's function as a molecular gatekeeper in olfaction is pivotal for our ability to detect and distinguish various odors in the environment.
Inhibiting Olfr834 is accomplished through a diverse array of mechanisms, both direct and indirect, aimed at attenuating its role in odor detection. Direct inhibitors focus on Olfr834 itself, either by binding to its active site or disrupting its associated signaling pathways. These inhibitors work by directly preventing the binding of odorants to Olfr834 or by interfering with the intracellular events initiated upon activation. On the other hand, indirect inhibitors take a different approach, influencing cellular pathways that intersect with Olfr834 signaling. By targeting pathways such as the MAPK/ERK or PI3K/Akt cascades, indirect inhibitors disrupt the downstream events triggered by Olfr834 activation, ultimately reducing its activity and signaling. These multifaceted mechanisms of inhibition are essential for researchers studying olfaction, shedding light on the intricate molecular processes underlying odor perception and providing insights into potential applications in various research domains.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin directly inhibits Olfr834 by binding to its active site and preventing its activation, leading to the inhibition of Olfr834 function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an indirect inhibitor that modulates the PI3K pathway, indirectly inhibiting Olfr834 by disrupting downstream signaling events associated with its activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a direct inhibitor of Olfr834, specifically targeting the MAPK/ERK pathway. It inhibits this pathway to directly reduce Olfr834 signaling and function. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin directly inhibits Olfr834 by disrupting calcium homeostasis, which is essential for Olfr834 activation and signal transduction, leading to its inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an indirect inhibitor that affects Olfr834 through the p38 MAPK pathway. By inhibiting this pathway, it indirectly reduces Olfr834 activity and associated signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an indirect inhibitor that acts on the PI3K/Akt pathway, indirectly inhibiting Olfr834 by inhibiting PI3K activity and disrupting downstream signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin indirectly inhibits Olfr834 through the mTOR pathway. It inhibits mTOR, leading to downstream effects that indirectly inhibit Olfr834 and its associated signaling pathways. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $31.00 $128.00 $454.00 | 45 | |
SB202190 indirectly inhibits Olfr834 by targeting the p38 MAPK pathway, indirectly influencing Olfr834 by inhibiting p38 MAPK and reducing its downstream effects. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride directly inhibits Olfr834 by blocking ion channels, preventing the generation of action potentials in olfactory neurons, and reducing Olfr834 signaling and function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an indirect inhibitor that affects Olfr834 through the JNK pathway. By inhibiting JNK, it indirectly influences Olfr834, leading to reduced cellular responses mediated by Olfr834. | ||||||